Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease

Javier Escaned1*, MD, PhD; Adrian Banning2, MD, PhD; Vasim Farooq3, MBChB, MRCP, PhD; Mauro Echavarria-Pinto1, MD; Yoshinobu Onuma4, MD, PhD; Nicola Ryan1, MB, BCh; Rafael Cavalcante5, MD, PhD; Carlos M. Campos5,6, MD; Bojan M. Stanetic5,7, MD; Yuki Ishibashi5, MD, PhD; Pannipa Suwannasom5,8, MD; Arie-Pieter Kappetein5, MD, PhD; David Taggart2, MD; Marie-Angèle Morel4, BSc; Gerrit-Anne van Es4, PhD; Patrick W. Serruys9, MD, PhD; on behalf of the SYNTAX II Study Group

1. Hospital Clinico San Carlos/Faculty of Medicine Complutense University, Madrid, Spain; 2. John Radcliffe Hospital, Oxford, United Kingdom; 3. Institute of Cardiovascular Sciences, Manchester Academic Health Sciences Centre, University of Manchester and

Aims: The applicability of the results of the SYNTAX trial comparing percutaneous coronary intervention (PCI) using first-generation drug-eluting stents (DES) with coronary artery bypass

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

chronic total occlusioncoronary artery diseasecoronary stentfractional flow reserveintravascular ultrasoundmultivessel diseasepercutaneous coronary interventionphysiologysyntax score ii

Coronary interventionsLeft main and multivessel disease

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial